Literature DB >> 9478924

The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS.

M Hallier1, A Lerga, S Barnache, A Tavitian, F Moreau-Gachelin.   

Abstract

Spi-1/PU.1 is an Ets protein deregulated by insertional mutagenesis during the murine Friend erythroleukemia. The overexpression of the normal protein in a proerythroblastic cell prevents its terminal differentiation. In normal hematopoiesis Spi-1/PU.1 is a transcription factor that plays a key role in normal myeloid and B lymphoid differentiation. Moreover, Spi-1/PU.1 binds RNA and interferes in vitro with the splicing process. Here we report that Spi-1 interacts in vivo with TLS (translocated in liposarcoma), a RNA-binding protein involved in human tumor-specific chromosomal translocations. This interaction appears functionally relevant, since TLS is capable of reducing the abilities of Spi-1/PU.1 to bind DNA and to transactivate the expression of a reporter gene. In addition, we observe that TLS is potentially a splicing factor. It promotes the use of the distal 5' splice site during the E1A pre-mRNA splicing. This effect is counterpoised in vivo by Spi-1. These data suggest that alteration of pre-mRNA alternative splicing by Spi-1 could be involved in the transformation of an erythroblastic cell.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9478924     DOI: 10.1074/jbc.273.9.4838

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Protein composition of human prespliceosomes isolated by a tobramycin affinity-selection method.

Authors:  Klaus Hartmuth; Henning Urlaub; Hans-Peter Vornlocher; Cindy L Will; Marc Gentzel; Matthias Wilm; Reinhard Lührmann
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-11       Impact factor: 11.205

2.  Functional cross-antagonism between transcription factors FLI-1 and EKLF.

Authors:  Joëlle Starck; Nathalie Cohet; Colette Gonnet; Sandrine Sarrazin; Zina Doubeikovskaia; Alexandre Doubeikovski; Alexis Verger; Martine Duterque-Coquillaud; François Morle
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

3.  The oncogenic TLS-ERG fusion protein exerts different effects in hematopoietic cells and fibroblasts.

Authors:  Junhui Zou; Hitoshi Ichikawa; Michael L Blackburn; Hsien-Ming Hu; Anna Zielinska-Kwiatkowska; Qi Mei; Gerald J Roth; Howard A Chansky; Liu Yang
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

4.  Heterogeneous nuclear ribonucleoprotein P2 is an autoantibody target in mice deficient for Mer, Axl, and Tyro3 receptor tyrosine kinases.

Authors:  Marko Z Radic; Kinjal Shah; Wenguang Zhang; Qingxian Lu; Greg Lemke; George M Hilliard
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

Review 5.  The TET family of proteins: functions and roles in disease.

Authors:  Adelene Y Tan; James L Manley
Journal:  J Mol Cell Biol       Date:  2009-09-24       Impact factor: 6.216

6.  TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins.

Authors:  L Yang; L J Embree; D D Hickstein
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 7.  The role of FUS gene variants in neurodegenerative diseases.

Authors:  Hao Deng; Kai Gao; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

8.  Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells.

Authors:  N Rekhtman; F Radparvar; T Evans; A I Skoultchi
Journal:  Genes Dev       Date:  1999-06-01       Impact factor: 11.361

Review 9.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

Review 10.  The RB/E2F pathway and regulation of RNA processing.

Authors:  Joseph Ahlander; Giovanni Bosco
Journal:  Biochem Biophys Res Commun       Date:  2009-05-03       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.